Q-omics provides the consensus-scored C2orf78 profile across patient tissues and cancer cell-line models. C2orf78 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C2orf78 is differentially expressed in 3, with the highest sampling consensus in KIRP. Additionally, C2orf78 RNA expression shows 6,369 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, KIRP, and STAD as cancer lineages where C2orf78 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2orf78 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2orf78 survival associations across molecular data types. C2orf78 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2orf78 RNA expression–survival associations across cancer types. High C2orf78 expression shows unfavorable associations in KIRC, DLBC, THCA, KIRP and LUSC, but favorable associations in SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C2orf78 RNA expression.
This table summarizes C2orf78 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for C2orf78. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2orf78 shows higher tumor expression in KIRP, LUAD and LUSC. The KIRP box plot shows higher C2orf78 RNA expression in tumor versus normal tissue (log2 FC = +0.039, t-test p = .002).
This table shows molecular features associated with C2orf78 in patient tissues and cancer cell lines. In patient samples, C2orf78 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, C2orf78 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
